Novo Nordisk Foundation has partnered with CARB-X investing US$25m to help SMEs to fight drug-resistant infections.
Calypso Biotech BV has entered into an agreement to be acquired by Novartis AG, which will pay. Calypso’s US$250m upfront upon closing plus of up to US$175.
Following in the footsteps of the European Medicines Agency (EMA), the US FDA is now also investigating the side effects of obesity blockbusters.
Boehringer Intelheim is expanding its antfibrotics pipeline licencing a first-in-class treatment for fibro-inflammatory diseases from Kyowa Kirin Co. Ltd.
Italian Resalis Therapeutics Srl has baged €10m in a Series A financing led by Sunstone Life Science Ventures to complete a Phase I study for RES-010 in obesity.
Hoffmann-La Roche AG has published details on the mechanism of action of its Phase I antibiotic Zosurabalpin (RG6006) that kills the carbapenem-resistant bug Acinetobacter baumannii.
.
Following its announcement from Oktober 2023 to take over the filgotinib business from Galapagos NV, Bologna-based Alfasigma SpA has signed the €170m deal.
Pharmaceutical giant AstrazZeneca wants to take over the Chinese company Gracell Biotechnologies in order to strengthen its cell therapy projects in a deal worth up to $1.2bn.
Cambridge-based Metrion Biosciences Ltd has secured £3.5m in new equity financing – led by Maven Capital Partners and a £1m contribution from existing investor, Gresham House Ventures.
Swiss LimmaTech Biologics and AbVacc Inc have agreed to co-develop AbVacc’s preclinical Staphylococcus aureus vaccine LBT-SA7 (formerly IBT-V02) in case of Phase I success.